\n \n \n “. concat(self. i18n. t(‘search. voice. recognition_retry’), “\n
RTHM collaborates on case studies of immune support supplements based on Tollovid™ 3CL inhibitors
Knowledge of Tollovid biomarkers for possible claims of structure function in the long COVID
New York, NY and Tel Aviv, ISRAEL, Aug. 05, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Todos Medical, Ltd. (OTCQB: TOMDF), a leading medical diagnostics and similar responses company, today announced the first patient samples won by its Long COVID Panel biomarker partnership between its qualified laboratory CLIA/CAP Provided Diagnostics and Amerimmune Diagnostics, a qualified CLIA/CAP laboratory that specializes in immunological diagnostics and a leader in clinical immunology and immunological assessment of acute and prolonged COVID. Samples from earned patients were ordered through Long COVID Clinic RTHM (Real Time Health Monitoring), the association’s first Long COVID Clinic client, collected at a Quest Diagnostics service center in the United States, and sent to Amerimmune’s lab in McLean, Virginia, for treatment. . The neutralizing antibody and general antibody portion of the panel is outsourced to Provided in Atlanta, GA and the knowledge is returned to Amerimmune for inclusion. in your report to the RTHM doctor. Biomarker tests included in the Long COVID Panel are covered through advertising insurance and Medicare.
In addition, RTHM physicians are now working with Todos’s subsidiary, 3CL Pharma, on their series of case studies on immune-aid supplements for the Tollovid™ 3CL protease inhibitor, and will now begin tracking biomarker knowledge with Long COVID Panel. The purpose is for data from the COVID long panel to be included in Everyone’s ongoing Tollovid case series to corroborate the perceived benefits to the patient. All intend to use the data collected in the case test series and its ongoing IRB-exempt market test to indicate the dosage of Tollovid recommendations for customers. In addition, Todos is planning a Phase 2 controlled trial in Tollovid.
“We are excited to see the pieces mixed together to enable our evaluation of Tollovid as a potentially vital complement to Long COVID,” said Dr. Lisa S. Jennifer Curtin, medical director of RTHM. ” We have had patients who have had wonderful effects with Tollovid and others who have not benefited as much. As such, we are now looking to expand our assessment of immune biomarkers in Long COVID to better understand which patients could derive benefits from Tollovid alone, or potentially in combination with other products, so that we can add key objective information to the clinical information we are collecting for each patient. . It is imperative that patients with prolonged COVID perceive this so that we can expand individualized diets to give each patient the most productive opportunity for good fortune and recovery.
To purchase Tollovid, visit Amazon or www. MyTollovid. com.
About RTHM: Founded in Redwood City, California, RTHM integrates remote clinical medicine and studies with complex virtual and molecular measurement technologies to deliver new diagnoses and remedies to patients faster, starting with Long COVID. RTHM is lately seeing patients in California, Oregon, Washington, Florida and Arizona in the United States with expansion plans in all 50 states. He is: www. rthm. com.
About Amerimmune Diagnostics LLCFounded in 2010, Amerimmune Diagnostics focuses on immunological testing as a solution to unfulfilled desires and the immediate diagnosis of immune disorders. Amerimmune combines cytometry immunophenotyping tests, expert interpretation and recommendations. Amerimmune tests allow the personal physician to optimally manage their patient population. For more information, visit www. amerimmunediagnostics. com.
About Tollovid® and Tollovid Daily™Tollovid and Tollovid Daily are oral nutritional supplements made with herbal ingredients that help and maintain a healthy immune system and also have hard 3CL protease inhibiting properties based on in vitro activity tests that show strong inhibition of 3CL protease activity. Tollovid and Tollovid Daily bind to the active site (receptor binding domain) of the 3CL protease. Tollovid has a 5-day dosing regimen, with four doses of 3 pills taken each day to provide the maximum immune systemArrayTollovid Daily is a daily immune product with a twice-daily dosing regimen. Preliminary information was recently announced from an ongoing study on the IRB exemption of consumers who have used the products to help with their COVID and Long COVID.
To purchase Tollovid, visit Amazon or www. MyTollovid. com.
About Tollovir®Tollovir® is an oral curative candidate for protease inhibitor 3CL and anti-cytokine for the nidovirus organization’s intervention of viruses that includes coronaviruses such as SARS-CoV-2, COVID-19, SARS-CoV-1, MERS and 229E. Tollvir is made from herbal ingredients qualified to achieve strong inhibition of 3CL protease in vitro, as well as strong anti-cytokine activity. Tollvir has effectively completed a Phase 2 clinical trial in Israel for the remedy of hospitalized patients with COVID-19. Tollvir will be developed for the treatment of hospitalized COVID-19 (severe and critical), moderate COVID-19, long-distance COVID, and potentially pediatric COVID-19.
About Todos Medical Ltd. Founded in Rehovot, Israel, with offices in New York, Todos Medical Ltd. (OTCQB: TOMDF) designs important diagnostic responses for the early detection of various types of cancer. The company’s proprietary infrared biochemical analyses (TBIs) are a patented generation of cancer screening that employs peripheral blood research that examines the influence of cancer on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. The two cancer screening tests evolved internally through All, TMB-1 and TMB-2, have earned ce marking in Europe. All recently acquired the U. S. -founded medical diagnostics company. USA Provided Diagnostics, Inc. to secure the rights of its qualified CLIA/CAP laboratory founded in Alpharetta, Georgia, which is recently conducting COVID PCR testing and Videssa, owned by Provista. ® breast cancer blood tests at the advertising stage.
All are also performing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer’s disease. Lymphocyte Proliferation Control (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to be exogenous mitogens. stimulation that activates them to enter the mobile cycle. Some diseases, including Alzheimer’s disease, are thought to be the result of compromised mobile machinery leading to aberrant re-entry of the mobile cycle through neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a replacement for neuronal mobile function, suggesting a non-unusual dating between PBLs and neurons in the brain.
All formed the Israel-based majority-owned joint venture 3CL Pharma, Ltd with NLC Pharma in March 2022 to consolidate all intellectual assets pursuing the progression of diagnostic tests targeting 3CL protease, as well as botanical and pharmaceutical 3CL protease inhibitors that target a basic replica mechanism of coronaviruses. 3CL Pharma, through the brand Todos, has announced the immunological nutritional supplement 3CL protease inhibitor Tollovid® in the United States, the curative drug candidate with dual mechanism protease inhibitor 3CL and anti-cytokine Tollvir® is approaching, in addition to presenting the 3CL diagnostic protease inhibitor TolloTest™.
For more information, visit https://www. todosmedical. com/.
Forward-Looking Statements Certain statements contained in this press release may possibly constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical trials and clinical progression systems. These forward-looking statements are based solely on existing control expectations and are subject to vital dangers and uncertainties that may also cause actual effects to differ materially from those described in the forward-looking statements, adding dangers and uncertainties related to the ProgressArray. timing, loading and effects of clinical trials and product progression systems; difficulties or delays in discharging regulatory approval or patent coverage for candidate products; festival of other biogeneration companies; and our ability to release more mandatory budget to carry out our research, development and commercialization activities. In addition, the following factors, among others, may also cause actual effects to differ materially from those described in the forward-looking statements: adjustments to generation and market requirements; delays or obstacles in starting our clinical trials; adjustments in the legislation; failure to expand and introduce new technologies, products and programs in a timely manner; lack of validation of our generation as we move forward and lack of acceptance of our strategies throughout the clinical community; inability to retain or attract key workers whose wisdom is essential to the progression of our products; unforeseen clinical difficulties that could possibly expand with our process; final product load higher than expected; loss of market share percentage and pressure on charges resulting from the festival; and laboratory effects that do not translate to similar intelligent effects under actual conditions, which may also cause actual effects or functionality to differ materially from those implied by such forward-looking statements. Except as otherwise required by law, Todos Medical assumes no legal responsibility to publicly disclose any revisions to such forward-looking statements to reflect events or events after the date hereof or to reflect the occurrence of unforeseen events. For a more detailed description of the dangers and uncertainties affecting Todos Medical, please refer to its reports filed periodically with the United States Securities and Exchange Commission.
All Corporate Contact 😀 HirschCFOTodos Medical917-983-4229 x 104Dan. h@todosmedical. com